Movahed Fatemeh, Heidari Ehsan, Sadeghi Dina, Rezaei Nejad Aida, Abyaneh Romina, Zarei Mehrshad, Beigi Farzan, Abdollahi Abolfazl, Shafiee Arman
Tehran University of Medical Sciences, Tehran, Iran.
Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Eur Child Adolesc Psychiatry. 2025 Feb;34(2):599-610. doi: 10.1007/s00787-024-02502-x. Epub 2024 Jun 24.
The use of antidepressants has been on the rise among adolescents and young adults, populations also increasingly at risk for type 2 diabetes. However, the relationship between antidepressant uses and diabetes incidence in these age groups remains poorly understood.
Adhering to PRISMA guidelines and the Cochrane Handbook, we conducted a comprehensive search in PubMed, Scopus, Embase, and Web of Science up to 21 February 2024, registering our protocol on PROSPERO (CRD42024516272).
Six studies, ranging from 16, 470 to 1, 582, 914 participants and spanning 2010 to 2023 across North America, Europe, and Asia, were included. The meta-analysis revealed a significant association between antidepressant use and diabetes onset, with 10 cases per 1, 000 observations (p < 0.01; I = 100%). Adolescents using high doses of antidepressants showed a 62% increased risk of developing diabetes compared to non-users or those on low doses (Risk ratio = 1.67; 95% CI 1.19-2.35; I = 87%; p < 0.01). The overall quality of the studies was high, with an average Newcastle-Ottawa Scale score of 7.66. Sensitivity analysis highlighted the robustness of these findings, except when removing specific studies, indicating potential sources of heterogeneity.
Antidepressant use in adolescents is associated with a significantly increased risk of diabetes onset, particularly at higher doses. This finding underscores the necessity for vigilant monitoring of glucose levels in this population and warrants further investigation into the underlying mechanisms and long-term outcomes.
抗抑郁药在青少年和青年中的使用呈上升趋势，而这些人群患2型糖尿病的风险也日益增加。然而，这些年龄组中抗抑郁药使用与糖尿病发病率之间的关系仍知之甚少。
遵循PRISMA指南和Cochrane手册，我们在PubMed、Scopus、Embase和Web of Science上进行了全面检索，截至2024年2月21日，并在PROSPERO（CRD42024516272）上登记了我们的方案。
纳入了6项研究，参与者人数从16470人到1582914人不等，时间跨度为2010年至2023年，涵盖北美、欧洲和亚洲。荟萃分析显示，使用抗抑郁药与糖尿病发病之间存在显著关联，每1000例观察中有10例发病（p<0.01；I=100%）。与未使用者或低剂量使用者相比，使用高剂量抗抑郁药的青少年患糖尿病的风险增加了62%（风险比=1.67；95%CI 1.19-2.35；I=87%；p<0.01）。研究的总体质量较高，纽卡斯尔-渥太华量表平均得分为7.66。敏感性分析突出了这些发现的稳健性，但排除特定研究时除外，这表明了潜在的异质性来源。
青少年使用抗抑郁药与糖尿病发病风险显著增加有关，尤其是高剂量使用时。这一发现强调了对该人群血糖水平进行密切监测的必要性，并值得进一步研究潜在机制和长期后果。
